CN Patent

CN108472336B — C型利尿钠肽变体在治疗骨骼发育不良中的用途

Assigned to Biomarin Pharmaceutical Inc · Expires 2022-05-31 · 4y expired

What this patent protects

本公开內容提供C型利尿钠肽(CNP)变体的用途，以及包含CNP变体肽的新颖医药组合物及制剂，用于治疗骨骼发育不良、骨骼发育不良的一种或多种症状如长骨生长或生长速度、和其它具有与骨骼发育不良及/或CNP相关的症状或组成的病变。

USPTO Abstract

本公开內容提供C型利尿钠肽(CNP)变体的用途，以及包含CNP变体肽的新颖医药组合物及制剂，用于治疗骨骼发育不良、骨骼发育不良的一种或多种症状如长骨生长或生长速度、和其它具有与骨骼发育不良及/或CNP相关的症状或组成的病变。

Drugs covered by this patent

Patent Metadata

Patent number
CN108472336B
Jurisdiction
CN
Classification
—
Expires
2022-05-31
Drug substance claim
No
Drug product claim
No
Assignee
Biomarin Pharmaceutical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.